As generative AI moves from novelty to infrastructure, the battle for inference speed has intensified. New data from late 2025 positions vLLM as the enterprise standard, even as specialized challengers claim the speed crown.
Recent discoveries published in Nature Communications and other major journals highlight the neuroprotective power of spermine and spermidine, signaling a pivot in dementia treatment strategies.
Rivian's confirmation of lidar integration in its Gen 3 platform has sent Luminar shares climbing, signaling a broader industry rejection of camera-only solutions.
Once the darling of the autonomous driving revolution, Luminar Technologies is navigating a perfect storm of financial distress and partnership ruptures.
In a major convergence of traditional banking and fintech, Fifth Third Bank will migrate its commercial card program to Brex's platform, aiming to replace legacy spreadsheets with AI-driven automation.
Dutch fintech leader Mollie secures acquisition of UK-based GoCardless, combining card and bank payment capabilities to serve over 350,000 businesses across Europe.
The machine-learning-powered lender signs a definitive agreement to acquire digital-first Grasshopper Bank, aiming for regulatory approval and strategic diversification by late 2026.
The global payments platform secures $330 million in Series G funding, establishing a dual headquarters in San Francisco and committing over $1 billion to American expansion.
In a major reversal of previous restrictions, the Trump administration clears high-end AI chip sales to China subject to a 25% surcharge, prioritizing trade revenue over absolute containment.
Following Australia's lead, the Danish government secures cross-party support to restrict digital access for minors, citing the need to reclaim stolen childhoods.
Researchers at King's College London have identified a significant association between theobromine levels and reduced markers of aging, sparking new debates on functional food regulation.
A breakthrough study published in Nature reveals that lowering levels of the FDX2 gene, traditionally seen as essential for life, can actually reverse damage in models of Friedreich's ataxia.